Changes in diurnal patterns related to changes in ozone levels.

Ozone is an ubiquitous air pollutant that affects both human health and vegetation. There is concern about the number of hours human populations in nonattainment areas in the United States are exposed to levels of O3 at which effects have been observed. As improvement in air quality is achieved, it is possible that O3 control strategies may produce distributions of 1-h O3 concentrations that result in different diurnal profiles that produce greater potential exposures to O3 at known effects levels for multiple hours of the day. These concerns have prompted new analysis of aerometric data. In this analysis, the change in the seasonally averaged diurnal pattern was investigated as changes in O3 levels occurred. For the data used in this analysis, 25 of the 36 sites that changed compliance status across years showed no statistically significant change in the shape of the average diurnal profile (averaged by O3 season). For 71 percent (10 out of 14) of the sites in southern California and Dallas-Fort Worth, Texas, that showed improvement in O3 levels (i.e., reductions in the number of exceedances over the years), but still remained in nonattainment, a statistically significant change in the shape of the seasonally averaged diurnal profile occurred. Based on the results obtained in this study, the evaluation of diurnal patterns may be useful for identifying the influence of changes in emission levels versus meteorological variation on attainment status. Using data from the southern California and Dallas-Fort Worth sites, which showed improvements in O3 levels, changes were observed in the seasonally averaged diurnal profiles.(ABSTRACT TRUNCATED AT 250 WORDS)

In vitro metabolism of the antimalarial agent primaquine by mouse liver enzymes and identification of a methemoglobin-forming metabolite.

From a mouse liver microsomal system, we have isolated and identified a methemoglobin-forming metabolite of primaquine (PQ). Evidence has been found for both O-dealkylation and hydroxylation of PQ to form a metabolite, 5,6-dihydroxy-8-(4-amino-1-methylbutylamino)quinoline, which is highly active in forming methemoglobin in both normal and glucose-6-phosphate dehydrogenase-deficient erythrocytes. It also actively decreases glutathione levels in glucose-6-phosphate dehydrogenase-deficient erythrocytes. The inhibitor SKF 525-A prevented metabolite formation while iproniazid and carbon monoxide did not inhibit metabolism completely but may have resulted in formation of a different unidentified metabolite. Mass spectrometry, HPLC, NMR, and other more indirect methods were used to help identify the metabolite. It was identified indirectly via a blue compound which results from extracting the actual metabolite from the incubation mixture with organic solvents under alkaline conditions in the presence of light. The blue compound was identified as a quinonimine in which the 8-amino side chain of PQ cyclizes to produce a third ring system.

Metabolism of 8-aminoquinoline antimalarial agents.

Some of the most effective antimalarial agents are derivatives of 8-aminoquinoline. The metabolic products of many of these compounds appear to be toxic to the erythrocytes of certain human subjects, especially those deficient in glucose-6-phosphate dehydrogenase. Although a number of studies have been conducted over many years, the metabolism of most of these compounds has not been determined. These studies are reviewed.Adult dogs dosed with tritium-labelled primaquine were observed to excrete approximately 16% of the injected radioactivity in the urine within 8 hours. Organic extracts of the urine were fractionated by thin-layer chromatography and the metabolic pattern obtained. Some primaquine was excreted along with at least five metabolites including 5-hydroxy-6-methoxy-8-(4-amino-1-methylbutylamino)quinoline (5HPQ) and a small amount of 6-hydroxy-8-(4-amino-1-methylbutylamino)quinoline (6HPQ). The 5HPQ could form a quinoneimine-type compound which may be a methaemoglobin-forming compound. This and other metabolites isolated from urine were found to be active methaemoglobin formers in in vitro studies. In vitro metabolism of primaquine by mouse liver enzymes also produced compounds capable of methaemoglobin formation. One of these had a blue colour when exposed to alkaline conditions, air, and light, and mass spectral data and nuclear magnetic resonance analysis indicated a structure similar to a 5,6-dihydroxy derivative of primaquine. However, the chemical structure of the metabolite was not identified in these studies.

Antiviral effect of cyclic amines on a 1969 isolate of A2 influenza.

Cyclooctylamine and amantadine inhibit the growth of 1969 isolates of A(2) influenza virus to a significant degree. There was slightly more inhibition of the virus by the cyclooctylamine (COA) than the amantadine; however, the dose of COA used was greater than the dose of amantadine. There was no significant difference between flasks treated 3 or 4 hr and those treated 2 hr. However, there was a curious relationship of more plaques in the flasks exposed to the two drugs for the longer intervals. Other experiments done with slight modifications in technique support the antiviral effect demonstrated in this experiment when the cell system is pretreated prior to virus infection. In two experiments, pretreating the cells for 2 hr with COA at 100 mug/ml but removing the drug solution and washing the cells prior to virus inoculation revealed no differences in plaque counts between controls and treated cells. This would indicate that the antiviral effect required the presence of the drug during the early stages of penetration of the cells by the virus particles.